Htg Molecular Diagnostics Stock Debt To Equity
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
HTG Molecular Diagnostics fundamentals help investors to digest information that contributes to HTG Molecular's financial success or failures. It also enables traders to predict the movement of HTG Stock. The fundamental analysis module provides a way to measure HTG Molecular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HTG Molecular stock.
HTG |
HTG Molecular Diagnostics Company Debt To Equity Analysis
HTG Molecular's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current HTG Molecular Debt To Equity | 2.52 % |
Most of HTG Molecular's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HTG Molecular Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, HTG Molecular Diagnostics has a Debt To Equity of 2.515%. This is 95.3% lower than that of the Health Care Technology sector and 96.76% lower than that of the Health Care industry. The debt to equity for all United States stocks is 94.84% higher than that of the company.
HTG Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HTG Molecular's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HTG Molecular could also be used in its relative valuation, which is a method of valuing HTG Molecular by comparing valuation metrics of similar companies.HTG Molecular is currently under evaluation in debt to equity category among its peers.
HTG Fundamentals
| Return On Equity | -3.43 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (3.15) % | |||
| Current Valuation | 2.56 M | |||
| Shares Outstanding | 2.21 M | |||
| Shares Owned By Insiders | 6.54 % | |||
| Shares Owned By Institutions | 0.74 % | |||
| Number Of Shares Shorted | 2.73 K | |||
| Price To Earning | (0.88) X | |||
| Price To Book | 6.26 X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 6.37 M | |||
| Gross Profit | (2.01 M) | |||
| EBITDA | (20.14 M) | |||
| Net Income | (21.59 M) | |||
| Cash And Equivalents | 14.1 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 4.83 M | |||
| Debt To Equity | 2.52 % | |||
| Current Ratio | 1.90 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (18.41 M) | |||
| Short Ratio | 0.03 X | |||
| Earnings Per Share | (17.10) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 53 | |||
| Beta | 0.99 | |||
| Market Capitalization | 1.06 M | |||
| Total Asset | 17.78 M | |||
| Retained Earnings | (229.93 M) | |||
| Working Capital | 7.38 M | |||
| Current Asset | 34.86 M | |||
| Current Liabilities | 6.32 M | |||
| Z Score | -20.86 | |||
| Net Asset | 17.78 M |
About HTG Molecular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HTG Molecular Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HTG Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HTG Molecular Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |